Sulfonylurea News and Research

RSS
FDA approves an expanded indication for BYETTA injection

FDA approves an expanded indication for BYETTA injection

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

NDA for Exenatide once weekly accepted for FDA review

NDA for Exenatide once weekly accepted for FDA review

Comprehensive review on sulfonylureas in the latest issue of Diabetic Hypoglycemia

Comprehensive review on sulfonylureas in the latest issue of Diabetic Hypoglycemia

Drugs may be 'magic bullet' for infants born with rare form of diabetes

Drugs may be 'magic bullet' for infants born with rare form of diabetes

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

FDA continues review of Takeda's NDA for Alogliptin

FDA continues review of Takeda's NDA for Alogliptin

Warning issued on dangers of diabetes drug Avandia

Warning issued on dangers of diabetes drug Avandia

Latest research suggests tight glucose control for diabetics

Latest research suggests tight glucose control for diabetics

Tredaptive and Janumet recommended for approval in European Union

Tredaptive and Janumet recommended for approval in European Union

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

For safety, NHLBI changes intensive blood sugar treatment strategy in trial of diabetes and cardiovascular disease

Caraco Pharmaceutical Labs announces FDA approval to market generic Metaglip

Caraco Pharmaceutical Labs announces FDA approval to market generic Metaglip

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.